Showing 15 posts of 146 posts found.


Axol Bioscience and StrataStem collaborate to deliver ‘clinical trial in a dish’ for Alzheimer’s disease

June 7, 2023
Research and Development Alzheimer's, Axol Bioscience, Neurology, StrataStem

Pluripotent stem cell technology provider Axol Bioscience has signed an exclusive agreement with UK-based StrataStem to access and commercialise its …

Eli Lilly to seek FDA approval for experimental Alzheimer’s drug

June 25, 2021
Medical Communications Alzheimer's, Eli Lilly, FDA

Eli Lilly plans to seek accelerated FDA approval for its experimental Alzheimer’s drug donanemab, announcing plans on Thursday to file …


Evonik and Cassava Sciences enter supply agreement for Alzheimer’s drug candidate

March 10, 2021
Research and Development Alzheimer's, Cassava Sciences, Evonik

Evonik has entered into an agreement to supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam, a drug candidate for …


Eli Lilly’s Alzheimer’s drug slows clinical decline in Phase II trial

January 11, 2021
Sales and Marketing Alzheimer's, Eli Lilly

Eli Lilly’s donanemab has shown significant slowing of decline in a composite measure of cognition and daily function in patients …


Leukaemia drug nilotinib shows promise against Alzheimer’s in small clinical study

May 29, 2020
Medical Communications Alzheimer's, leukaemia

The leukemia drug nilotinib has shown promise in reducing the effects of Alzheimer’s disease and while having safe and minimal …


Roche’s experimental Alzheimer’s drug does not meet primary endpoint in clinical trials

February 10, 2020
Sales and Marketing Alzheimer's, Roche, roche Alzheimer

Roche has said its experimental drug, gantenerumab, did not meet its primary endpoint in people who have an inherited form …


Biogen picks up Pfizer’s Phase 1 therapy for Alzheimer’s symptoms in potential $700m deal

January 14, 2020
Manufacturing and Production, Sales and Marketing Alzheimer's, Biogen, Pfizer, pharma

Biogen has entered into an agreement with Pfizer to acquire the latter’s Phase 1 candidate PF-05251749 in order to develop …


LSD treatment for Alzheimer’s patients proves safe in recent trial

December 19, 2019
Business Services Alzheimer's, FDA, LSD, Magic mushrooms, psilocybin

The results of a Phase 1 clinical trial shows that Lysergic Acid Diethylamide (LSD) can be microdosed safely, and potentially …


China green lights first novel Alzheimer’s therapy since 2003

November 4, 2019
Sales and Marketing Alzheimer's, China, Green Valley, Oligomannate, pharma

Shanghai Green Valley Pharmaceuticals has announced that its therapy Oligomannate (GV-971) has secured marketing approval from China’s National Medical Products Administration (NMPA) …

Axon seeks global partner after positive Phase 2 data for Alzheimer’s vaccine

September 10, 2019
Manufacturing and Production, Sales and Marketing Alzheimer's, Alzheimers, Axon

Axon Neuroscience has announced data from its Phase 2 trial ADAMANT for the first-in-class vaccine AADvac1 to slow the progression …


Novartis and Amgen halt trials into Alzheimer’s drug after patients get worse

July 12, 2019
Medical Communications Alzheimer's, Amgen, Banner Alzheimer's Institute, Novartis, dementia, pharma, research

Novartis, Amgen and Banner Alzheimer’s Institute have dropped a study into investigational Alzheimer’s drug CNP520 (umibecestat) after some patient’s conditions …

Pfizer supressed research suggesting arthritis drug Enbrel reduced risk of Alzheimer’s by 64%

June 6, 2019
Research and Development Alzheimer's, Drug therapy, Pfizer, dementia, pharma

Pfizer supressed data suggesting that their drug Enbrel reduced the risk of patients developing Alzheimer’s disease by 64%. In 2015, …


Scientists identify new form of dementia

May 1, 2019
Research and Development AD, Alzheimer's, dementia, late, neuroscience

A team of scientists from Britain and the United States have described a new form of dementia, according to a …

Google accused of profiting from misleading dementia supplement ads

March 26, 2019
Manufacturing and Production Alzheimer's, dementia, google, pseudomedicine, search engines, tech

Google has been accused of profiting from false hope after running adverts for unproven dementia treatments which can cost as …


Biogen and Eisai discontinue Phase 3 Alzheimer’s trial

March 21, 2019
Research and Development Alzheimer's, Biogen, CNS, Eisai, mental health

Biogen and Eisai have announced their decision to discontinue a Phase 3 trial looking into the efficacy and safety of …

Latest content